Two New Indications of Kisqali Approved in US for Advanced Breast Cancers
News
Kisqali (ribociclib) now can be used in combination with an aromatase inhibitor as first-line therapy for all women with HR-positive, HER2-negative advanced or metastatic breast cancer in the United States, ... Read more